Trial Profile
A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Halofuginone (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Therapeutic Use
- 06 Aug 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
- 21 Sep 2005 New trial record.